


RECEIVED

AUG 26 2002

TECH CENTER 1600/2900

Amdt B/ #  
J 8.29.02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of: **CHARI**

Application No: **09/671,995**

Group Art Unit: **1642**

Filed: **September 29, 2000**

Examiner: **S. Rawlings, Ph.D.**

For: **Compositions and Methods for Treating Cancer Using  
Immunoconjugates and Chemotherapeutic Agents**

Docket No: 104322.198 US1

Commissioner of Patents and Trademarks  
Washington, DC 20231

**RESPONSE TO OFFICE ACTION MAILED MAY 24, 2002**

In response to the Office Action mailed May 24, 2002 in the above-referenced case, please consider the following. Additionally, please provide any extensions of time which may be necessary and charge any additional fees which may be due, or credit any overpayment, to Deposit Account 08-0219, but not to include any payment of issue fees.

**IN THE CLAIMS:**

Please amend the claims as indicated in Appendix 1. A marked-up version of the amended claims is set forth in Appendix 1. A clean version of the claims is set forth in Appendix 2

**REMARKS**

Entry of the amendment and reconsideration of the application are respectfully requested. After entry of the amendment, claims 1-32, 40, 41 and 44-89 will be pending. Claims 52 and 74 have been amended to indicate that the monoclonal antibody is humanized N901 or C242 and the fragment of said monoclonal antibody is a fragment of humanized N901 or humanized C242. Moreover, claims 53 and 75 have been amended to indicate that the fragment of the recited monoclonal antibody is Fv, Fab, Fab' or F(ab')<sub>2</sub>. Such amendments are fully supported in the application, and in the claims as drafted. Claims 50, 51, 72 and 73 have been amended to indicate that